Skip Nav Destination
About the Journal
Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.Read More About the Journal
Impact Factor
29.1
Featured Articles
Continuing the Conversation
Luis A. Diaz; Lewis C. Cantley
Cancer Hallmarks: Piecing the Puzzle Together
Maria P. Alcolea, et al.
The Hallmarks of Precancer
Mary M. Stangis, et al.
Noted This Week
Soon, there may be a new standard of care for patients with previously treated KRASG12C-mutated colorectal cancer, researchers announced at the AACR meeting. The phase I/II KRYSTAL-1 trial, which was concurrently published, tested the KRASG12C inhibitor adagrasib (Krazati; Mirati) plus the EGFR inhibitor cetuximab (Erbitux) in 94 patients with metastatic disease. The objective response rate was 34%, and the disease control rate was 85.1%, with responses lasting a median of 5.8 months (Cancer Discov 2024 Apr 8 [Epub]). The median progression-free survival (PFS) was 6.9 months, and the median overall survival (OS) was 15.9 months. The study did not test the combination against adagrasib alone, but the researchers said that the drug duo compared favorably with historical data.
Trending - Altmetric
Read the article titled, The BTK Inhibitor ARQ 531 Targets Ibrutinib Resistant CLL and Richter's Transformation
Last mentioned on Wednesday April 17 2024
Read the article titled, Combining TIGIT blockage with MDSC inhibition hinders breast cancer bone metastasis by activating anti-tumor immunity.
Last mentioned on Thursday April 18 2024
Read the article titled, Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
Last mentioned on Wednesday April 17 2024
The Twitter live feed is not currently active.
Keep up to date with Cancer Discovery
Advertisement